Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.80 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.80 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.80 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.80 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.80 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.80 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.80 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16223109 | 0.90 | HDAC3 (0.80) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL13029066 | 0.90 | HDAC3 (0.84) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| Abexinostat SCHEMBL29489677 | 0.89 | HDAC6 (1.00) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL13029067 | 0.89 | HDAC3 (0.82) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| Potassium Ion SCHEMBL443346 | 0.89 | HDAC3 (0.82) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL443345 | 0.89 | HDAC3 (0.82) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL14933674 | 0.89 | HDAC3 (0.76) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL443054 | 0.89 | HDAC3 (0.82) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| Abexinostat SCHEMBL444280 | 0.89 | HDAC6 (1.00) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL15992081 | 0.89 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834054-B2 | Use of the histone deacetylase inhibitor N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]benzamide (aka CRA-24781, PCI-24781) for treating myelogenous leukemia (MML) or acute myelogenous leukemia (AML), optionally in combination therapy | PHARMACYCLICS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090220454-A1 | Use of the histone deacetylase inhibitor N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]benzamide (aka CRA-24781, PCI-24781) for treating myelogenous leukemia (MML) or acute myelogenous leukemia (AML), optionally in combination therapy | PHARMACYCLICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | HDAC3 1/4885HDAC1 2/4885HDAC2 13/4885 |
| US-20090220454-A1 | Use of the histone deacetylase inhibitor N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]benzamide (aka CRA-24781, PCI-24781) for treating myelogenous leukemia (MML) or acute myelogenous leukemia (AML), optionally in combination therapy | HDAC8, HDAC3, HDAC1 | HDAC3 2/4885HDAC1 3/4885HDAC2 10/4885 |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | HDAC3 1/4885HDAC1 2/4885HDAC2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.